Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | MPO | P05164 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | KDM5A | P29375 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | GFER | P55789 | 1/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ESRRG | P62508 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17865779 | 0.91 | LMNA (0.58) | LMNAHTTCYP2C9SMN1; SMN2MAPT | |
| SCHEMBL28915715 | 0.89 | LMNA (0.48) | TSHRMPOCYP3A4KDM5ABLM | |
| SCHEMBL2522600 | 0.84 | LMNA (0.53) | LMNAHTTCYP2C9SMN1; SMN2MAPT | |
| SCHEMBL25753418 | 0.83 | LMNA (0.51) | LMNAHTTCYP2C9SMN1; SMN2MAPT | |
| SCHEMBL2264435 | 0.83 | ALDH1A1 (0.61) | LMNAHTTSMN1; SMN2MAPTMEN1 | |
| SCHEMBL13762029 | 0.83 | HDAC1 (0.67) | LMNAHTTSMN1; SMN2MAPT | |
| SCHEMBL13701770 | 0.83 | HDAC2 (0.59) | TSHRLMNAHTTSMN1; SMN2MAPT | |
| SCHEMBL3716265 | 0.83 | SRD5A2 (0.53) | TSHRLMNAHTTCYP2C9SMN1; SMN2 | |
| SCHEMBL10577753 | 0.81 | LMNA (0.50) | LMNAHTTCYP2C9SMN1; SMN2MAPT | |
| SCHEMBL8920815 | 0.81 | LMNA (0.50) | LMNAHTTCYP2C9SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3589606-B1 | TRANSITION METAL-CATALYZED PROTODECARBOXYLATION OF ALPHA-HALO-ACRYLIC ACID DERIVATIVES | BOEHRINGER INGELHEIM INT (DE) | 2023-09-20 | — | — | EP | disclosed |
| EP-3626699-B1 | SSAO INHIBITOR | SHANDONG DANHONG PHARMACEUTICAL CO LTD (CN) | 2023-07-12 | — | — | EP | disclosed |
| CN-110914234-B | Amine compound for inhibiting SSAO/VAP-1 and application thereof in medicine | 广东东阳光药业有限公司 | 2023-06-23 | — | — | CN | disclosed |
| US-11584801-B2 | Anti-5T4 antibodies and antibody-drug conjugates | BYONDIS B.V. (NL) | 2023-02-21 | — | — | US | disclosed |
| CN-108341752-B | Amine compound for inhibiting SSAO/VAP-1 and application thereof in medicine | 广东东阳光药业有限公司 | 2022-12-23 | — | — | CN | disclosed |
| US-11382982-B2 | Duocarmycin ADCs showing improved in vivo antitumor activity | BYONDIS B.V. (NL) | 2022-07-12 | — | — | US | disclosed |
| US-20210388115-A1 | SITE-SPECIFIC CONJUGATION OF LINKER DRUGS TO ANTIBODIES AND RESULTING ADCS | BYONDIS BV (NL) | 2021-12-16 | — | — | US | disclosed |
| US-20210386867-A1 | FILTERABLE DUOCARMYCIN-CONTAINING ANTIBODY-DRUG CONJUGATE COMPOSITIONS AND RELATED METHODS | BYONDIS B.V. (NL) | 2021-12-16 | — | — | US | disclosed |
| US-20210317231-A1 | ANTI-5T4 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | BYONDIS BV (NL) | 2021-10-14 | — | — | US | disclosed |
| US-11136633-B2 | Site-specific conjugation of linker drugs to antibodies and resulting ADCS | BYONDIS B.V. (NL) | 2021-10-05 | — | — | US | disclosed |
| EP-0971709-A4 | NOVEL COMPOUNDS USEFUL AS NEURO-PROTECTIVE AGENTS | LILLY CO ELI (US) | 2001-04-11 | — | — | EP | disclosed |
| EP-1077699-A1 | AMIDE THERAPEUTICS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | CENTAUR PHARMACEUTICALS, INC. (US) | 2001-02-28 | — | — | EP | disclosed |
| EP-0971709-A1 | NOVEL COMPOUNDS USEFUL AS NEURO-PROTECTIVE AGENTS | ELI LILLY AND COMPANY (US) | 2000-01-19 | — | — | EP | disclosed |
| WO-1999059582-A1 | AMIDE THERAPEUTICS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | CENTAUR PHARMACEUTICALS, INC. (US) | 1999-11-25 | — | — | WO | disclosed |
| WO-1999018091-A1 | NOVEL COMPOUNDS USEFUL AS NEURO-PROTECTIVE AGENTS | ELI LILLY AND COMPANY (US) | 1999-04-15 | — | — | WO | disclosed |
| EP-0908454-A2 | Oxazoles, thiazoles, oxazolines, oxadiazoles and benzoxazoles useful as neuro-protective agents | ELI LILLY AND COMPANY (US) | 1999-04-14 | — | — | EP | disclosed |
| WO-1999009979-A1 | METHOD FOR TREATING NEUROPATHIC PAIN | ELI LILLY AND COMPANY (US) | 1999-03-04 | — | — | WO | disclosed |
| WO-1999009829-A1 | METHOD FOR TREATING PAIN | ELI LILLY AND COMPANY (US) | 1999-03-04 | — | — | WO | disclosed |
| WO-1999009980-A1 | METHOD FOR TREATING PAIN | ELI LILLY AND COMPANY (US) | 1999-03-04 | — | — | WO | disclosed |
| WO-1998015274-A1 | NOVEL COMPOUNDS USEFUL AS NEURO-PROTECTIVE AGENTS | ELI LILLY AND COMPANY (US) | 1998-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11136633-B2 | Site-specific conjugation of linker drugs to antibodies and resulting ADCS | MCL1, CD44, GLS2 | TSHR 1810/4885MPO 1199/4885CYP3A4 1184/4885 |
| US-20210386867-A1 | FILTERABLE DUOCARMYCIN-CONTAINING ANTIBODY-DRUG CONJUGATE COMPOSITIONS AND RELATED METHODS | DAD1, MGAM, DDOST | TSHR 4423/4885MPO 701/4885CYP3A4 1031/4885 |
| US-20210317231-A1 | ANTI-5T4 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | SLC5A7, SLC26A4, FUT4 | TSHR 475/4885MPO 2973/4885CYP3A4 934/4885 |
| US-11382982-B2 | Duocarmycin ADCs showing improved in vivo antitumor activity | CD38, BRCA1, TP53 | TSHR 2833/4885MPO 476/4885CYP3A4 2141/4885 |
| US-20210388115-A1 | SITE-SPECIFIC CONJUGATION OF LINKER DRUGS TO ANTIBODIES AND RESULTING ADCS | MCL1, CD44, GLS2 | TSHR 1810/4885MPO 1199/4885CYP3A4 1184/4885 |
| US-11584801-B2 | Anti-5T4 antibodies and antibody-drug conjugates | SLC5A7, SLC26A4, FUT4 | TSHR 475/4885MPO 2973/4885CYP3A4 934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.